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Abstract 
 
Prospective structure based virtual fragment screening methodologies on two GPCR targets 
namely the dopamine D3 and the histamine H4 receptors with a library of 12905 fragments 
were evaluated. Fragments were docked to the X-ray structure and the homology model of the 
D3 and H4 receptors, respectively. Representative receptor conformations for ensemble 
docking were obtained from molecular dynamics trajectories. In vitro confirmed hit rates 
ranged from 16% to 32%. Hits had high ligand efficiency (LE) values in the range of 0.31-
0.74 and also acceptable lipophilic efficiency. The X-ray structure, the homology model and 
structural ensembles were all found suitable for docking based virtual screening of fragments 
against these GPCRs. However, there was little overlap among different hit sets and 
methodologies were thus complementary to each other. 
 
1. Introduction 
 
Fragment-based lead discovery (FBLD) has become a feasible alternative to traditional lead 
finding approaches in drug discovery employed both by industry and academic groups [1]. It 
has been demonstrated that starting from polar, low molecular weight – typically < 250 Da or 
less than 20 heavy atoms – compounds, leads and drugs with better physico-chemical 
properties can be achieved [2] even for difficult targets [3]. This view is supported by the 
increasing number of drug candidates recently entering clinical trials and one already 
approved drug originating from a fragment hit [4]. Since weakly binding fragments require 
sensitive, but typically lower throughput biophysical detection methodologies (such as SPR, 
NMR, XRD, MS), and also because fragments are usually optimized using structural 
information, there is an ongoing interest in virtual methodologies capable of predicting 
fragment binding and providing reliable binding modes for them. Molecular docking is an in 
silico tool aiming to predict the binding mode and binding free energy of druglike molecules. 
It has been shown that various docking programs have similar performance in pose prediction 
for fragments (especially for fragments of high ligand efficiency) and druglike molecules [5-
7], since fragments usually exploit the specific interactions available at protein hot spots [8]. 
In virtual screening setups, where the objective is the ranking of fragments by binding free 
energy, the modest enrichment of actives [9,10] shall be improved using more accurate 
binding free energy functions. One of these methods is the computationally intensive MM-
PBSA rescoring method that was used to improve enrichments [11,12]. It has also been 
suggested that incorporating receptor flexibility in docking (not only in the rescoring phase) 
might be beneficial for virtual screening enrichments. Various protocols have been published 
taking into account different ranges of protein flexibility [13]. The simplest approach is the 
use soft potentials to account for small side-chain movements. Larger movements might be 
considered using side chain rotamer libraries. Docking into appropriately selected multiple 
protein conformations (ensemble docking) is a parallelizable and resource effective way of 
handling the flexibility of the entire protein. The most computationally intensive methods 
attempt the simultaneous conformational sampling of the receptor and the ligand, such as 
Schrödinger’s Induced Fit Docking (IFD) [14] application, or running molecular dynamics 
(MD) simulation on each individual protein-fragment complex. Different receptor 
conformations for ensemble docking can be obtained from multiple crystal structures or NMR 
structures if such data is available. However, structural studies on membrane proteins, such as 
G protein-coupled receptors (GPCRs) typically represent great challenges. Despite recent 
progress in GPCR crystallization still only a small percentage of structures have been 
unveiled. In such a case homology modeling may be used to obtain an atomistic model of the 
receptor. Structurally diverse receptor models can be obtained using different GPCR template 
structures during homology modeling. Diverse conformations may also be sampled by MD 
simulation, Monte Carlo or low-mode conformational search starting from a single homology 
model [15,16]. De Graaf et al. used a homology model of the histamine H3 receptor and 
subsequent MD sampling to provide the conformations used for retrospective and prospective 
virtual fragment screening [17]. In the present study we performed prospective virtual 
fragment screening on the available dopamine D3 receptor crystal structure and a homology 
model of the histamine H4 receptor based on the recently solved histamine H1 receptor 
crystal structure. Snapshots from all-atom membrane-embedded MD simulations were also 
used for ensemble virtual screening of the same fragment library. Screening performance of 
the different protocols were compared analyzing hit rates and hit compounds obtained by 
docking to the single structure and the conformational ensembles.  
 
2. Computational methods 
 
2.1. Homology modeling and crystal structure preparation 
 
The construction of the histamine H4 receptor homology model was described previously 
[18]. Briefly, the H4 amino acid sequence from the UniProt server (http://www.uniprot.org/) 
was aligned to the sequence of the template, the 3.1 Å resolution X-ray structure of the human 
histamine H1 receptor (PDB code: 3RZE) using Prime 3.0 [19]. The kink in helix TM4 was 
modeled based on the human β2-adrenergic receptor (PDB code: 2RH1). The JNJ7777120 
ligand was first manually docked into the receptor, and then the 5 Å environment of the ligand 
was subjected to minimization with two H-bond constraints using MacroModel 9.9 [20]. 
JNJ7777120 was re-docked into the minimized structure using IFD [14,21] in the Schrödinger 
Suite 2011. Finally the whole structure was subjected to Impref restrained minimization in the 
Protein Preparation Wizard [22]. Chain A of the dopamine D3 crystal structure (PDB code: 
3PBL) was subjected to the Protein Preparation Wizard workflow with default settings, that 
included assigning bond orders, adding hydrogens, creating disulfide bonds, optimization of 
the H-bond network and finally a restrained minimization of the complex. 
 
 
 
2.2. Molecular dynamics simulations and ensemble preparation 
 
The details of molecular dynamics simulations were described elsewhere [18]. Briefly, all-
atom POPC membrane-embedded MD simulations were run starting from the homology 
model of the histamine H4 receptor JNJ7777120 complex and the crystal structure of the 
dopamine D3 receptor eticlopride complex using ff99SB force field for protein and GAFF 
force field for lipid and ligand atoms in the NAMD 2.7 [23] software. The systems were 
equilibrated with subsequent steps of i) 3200 steps minimization with restrained protein and 
ligand atoms ii) 3200 steps unrestrained minimization iii) heating in NVT ensemble to 310 K 
in 40 ps with restrained protein and ligand atoms iv) 1 ns MD simulation in NpzγT ensemble 
with restrained protein and ligand atoms v) 1 ns MD simulation in NpzγT ensemble with 
gradual removal of the restraints. 20 ns production runs in NpzγT ensemble were conducted 
for both systems. Receptor conformations of the two trajectories were clustered using the 
average linkage method in the ptraj program from the AmberTools package [24] based on the 
RMSD of the amino acid residues that made up 90% cumulative occurrence in the 5 Å 
environment of the ligand. This method provided 28 representative conformations for the 
histamine H4 receptor and 27 representative conformations for the dopamine D3 receptor. All 
representatives were subjected to Impref restrained minimization in the Protein Preparation 
Wizard. 
 
2.3. Single structure and ensemble docking methodologies 
 
We collected 12905 fragment-like compounds from our in-house collection complying with 
an extended version of the Rule of Three: having an MW ≤ 300 Da, logP ≤ 3, number of H-
bond donors and acceptors ≤ 3, number of rotatable bonds ≤ 6, PSA < 130 Å2, containing 1-3 
rings and no reactive functionalities (see property distributions and diversity assessment in the 
Supporting Information). The structures of these fragments were prepared using LigPrep 2.5 
[25]. The dominant protonation and tautomeric state at pH 7.4 was calculated using Epik 2.2 
[26]. Their logP was calculated using the ChemAxon cxcalc utility [27]. In the single 
structure investigation the 12905 fragments were docked into the binding site of the dopamine 
D3 X-ray structure and the histamine H4 homology model. Then in the ensemble docking 
approach the fragment set was docked into the binding sites of all representatives from the D3 
and H4 MD trajectories. Glide 5.7 [28-31] software was used for docking. Grids for the initial 
homology model and crystal structure, as well as for the representatives from the MD 
trajectories were centered on the ligand centroids, and had dimensions of 14×14×14 Å for the 
inner box (which contains the ligand centroid during docking) and 44×44×44 Å for the outer 
box (which contains all ligand atoms during docking) to ensure that sampling of the binding 
mode was not biased by the grid size. Docking calculations were conducted using the single 
precision (SP) mode [5], with post-dock minimization performed for 15 poses. Only the top 
pose for each fragment by the Emodel scoring function was saved, which were ranked by the 
GlideScore scoring function for each individual receptor conformation. For single structure 
docking to the D3 X-ray structure and the H4 homology model, the top 50 compounds from 
the GlideScore ranked list were chosen for biological testing. In the ensemble docking 
approach mean ranks and their standard deviations calculated over the ensemble were used for 
evaluating each individual compound. Compounds having a mean rank lower than 500 were 
selected for biological testing. This cutoff gave a similar number of compounds to be tested as 
for the single structure case: 56 for the dopamine D3 receptor and 50 for the histamine H4 
receptor. 
 
3. Results and discussion 
 3.1. Receptor binding sites 
 
While the histamine H1 and H4 receptors share 40% amino acid identity in the 
transmembrane region and they recognize the same endogenous ligand, there are substantial 
differences in their binding sites. For example Asn147
4.57
 in H4 is equivalent to Trp158
4.56
 in 
H1, Leu175
5.39
 to Lys191
5.39
, Glu182
5.46
 to Asn198
5.46
 and Gln347
7.42
 to Gly457
7.42
. Also, 
mutation of Asn147
4.57
 and Glu182
5.46
 showed significant alteration to JNJ7777120 inhibition 
constants [32]. Thus the initial homology model featured two specific H-bonds of 
JNJ7777120 to Asp94
3.32
 and Glu182
5.46
 as shown in Fig. 1A. In the course of the molecular 
dynamics simulation the H4 receptor binding site appears to be relatively rigid based on side 
chain χ1 and χ2 angles of the interacting residues (Fig. 2A). Met150
4.60
 is quite flexible and 
Leu175
5.39
 assumes two different rotamer states, but these variations don’t alter the binding 
pattern of the ligand. However Glu182
5.46
 also adopts two main rotamer states, which causes 
some variability in the ligand position within the binding site. The ionic interaction to 
Asp94
3.32
 is mostly uninterrupted and surprisingly Gln347
7.42
 also formed an H-bond with the 
carbonyl group of JNJ7777120 in some of the representative frames. The D3 receptor binding 
site is also quite rigid, only Cys114
3.36
, Ser196
5.46
 and Thr369
7.39
 assume an alternative 
rotamer state featuring alternative H-bonds in a few representative structures (Fig. 2B). 
Interestingly, His349
6.55
 was quite flexible, which seems to be in a tight H-bond network in 
the crystal structure. The ligand interaction pattern changed little; the highest RMSD from the 
crystal binding mode was 2.4 Å after superposition of the proteins, the ethylpyrrolidine part of 
eticlopride was able to move somewhat without losing the ionic interaction with Asp110
3.32
 
(shown in Fig. 1B). 
 
3.2. Single structure and ensemble docking results 
 
In the case of the H4 receptor the fragment library was docked to the homology model and to 
the 28 representative conformations collected from the molecular dynamics simulation, while 
for the D3 receptor docking has been carried out to the prepared X-ray structure and the 27 
representative conformations from simulation. In both cases individual structural models 
provided a wide range of docking scores (GlideScore) but the single starting structure 
provided lower scores overall than the selected frames from MD. For example the docking 
scores of the top scoring fragments in each of the H4 frames ranged from -8.093 to -9.920 but 
it was -10.686 for the homology model. Similarly for the D3 receptor top scores ranged from -
8.063 to -9.514 but it was -9.796 for the X-ray structure. Since binding sites appeared to be 
quite rigid during the MD simulation, these differences in the docking scores can be attributed 
to little variations in side chain geometries, indicating that specific interactions in the X-ray 
structure and homology model are in the optimal geometry with their respective ligands, 
while they loosen up during MD. Thus the distribution of the top scores indicate that X-ray 
structures and homology models have optimized protein-ligand interaction patterns while MD 
snapshots represent more diverse conformations, which in turn might be able to select more 
chemotypes than those optimized structures. For the single structures it was straightforward to 
select the top 50 fragments by GlideScore ranking for biological testing. For ensemble 
docking two different data fusion methods were considered. The rank-by-rank and rank-by-
number consensus scoring schemes were investigated; the rank-by-vote method was shown to 
provide poorer results [33]. In the rank-by-rank scheme ligands are finally ranked by the mean 
of their rank numbers in each docking run to the representative structures. It was also 
investigated whether low standard deviation of ranks accompanies low mean ranks and we 
confirmed a strong correlation between average rank and its standard deviation for fragments 
having mean rank lower than 500 (see Fig. 3). These fragments also fell in the top 1% of the 
ranked database in more than 3 representative frames both for the D3 and the H4 receptor. 
The correlation becomes less pronounced for higher mean ranks and eventually turns around 
for compounds ranked high by all MD frames. In the rank-by-number scheme ligands are 
finally ranked by the mean of their docking scores. It has been shown that using the mean of 
standardized Z-scores outperforms the average of the original scores; hence in this study the 
standardized GlideScores were evaluated. However, non-normal distribution of the 
GlideScores was observed for the fragment library and since there was two-thirds overlap 
between the top 50 selected by the rank-by-rank and rank-by-number schemes, the first one 
was finally used to select fragments for biological testing. 
 
3.3. Pharmacological activities 
 
In the case of the D3 receptor 50 fragments from the X-ray structure docking run and 56 
fragments from the ensemble docking run were selected for biological testing. These lists had 
14 compounds in common, thus altogether 92 fragments were tested for D3 binding affinity in 
10 µM concentration. In the case of the H4 receptor 50 fragments from the initial homology 
model docking run and also 50 fragments from the ensemble docking run were selected for 
biological testing. These lists had 15 compounds in common, thus altogether 85 fragments 
were tested for H4 binding affinity in 10 µM concentration. The only 30% overlap between 
the different methods is not altogether surprising since the crystal structure and the homology 
model select compounds that bind to a specific receptor conformation while ensemble 
docking selects compounds that have reasonably good interaction patterns with multiple 
receptor conformations. It has also been shown that the overlap of hits picked up by different 
screening paradigms likewise might be very low [34]. In the case of D3 25 virtual hits 
provided higher than 20% inhibition in the biological assay, corresponding to a combined hit 
rate of 27% (hit rates are summarized in Table 1). Out of these 9 came from the crystal 
structure docking run (18%  hit rate) and 18 from the ensemble docking run (32% hit rate) 
with only 2 overlapping compounds. Binding affinity was determined for the 8 best 
compounds exhibiting higher than 75% inhibition at 10 µM concentration (Table 2). Ki values 
were in the range of 0.17 to 2.8 µM. Besides binding affinity various ligand efficiency metrics 
are applied in fragment-based lead discovery in order to prioritize fragment hits. These 
metrics incorporate molecule size either in terms of molecular mass or heavy atom count and 
lipophilicity usually represented with the octanol-water partition coefficient logP. In this 
study ligand efficiency (LE = –RTlnKi/Nheavy) and lipophilic ligand efficiency (LELP = 
logP/LE) [2] were considered. Since the D3 ligands identified here are very tight binders, LE 
values much higher than the usually accepted lower limit of 0.3 were obtained. As they are 
also on the lower side of lipophilicity, LELP values mostly below 5 were found, compounds 2 
and 4 being the most favorable. In the case of H4 somewhat fewer, 15 virtual hits provided 
higher than 20% inhibition in the biological assay, corresponding to a combined hit rate of 
18%. Out of these 11 came from the homology model docking run (22%  hit rate) and 8 from 
the ensemble docking run (16% hit rate) with 4 overlapping compounds. Five of them were 
unavailable in the compound collection in sufficient quantity for binding affinity 
measurement but Ki values were determined for the remaining 10 compounds (Table 3). 
These were in the range of 8.4 to 75 µM, an order of magnitude higher than the hits for the D3 
receptor. The lower hit rate and the lower binding affinities indicate a difference in the 
chemical tractability of the two receptors. LE values of the H4 ligands were correspondingly 
not as high as for D3 but still above the 0.3 limit up to 0.45. Also, the H4 ligands were 
somewhat more lipophilic resulting in higher LELP values, though still below 10. Especially 
fragments 10 and 18 showed favorable LE and LELP values. Taken together, these fragments 
would be suitable starting points for medicinal chemistry optimization; however, the scope of 
this study was to analyze the impact of different virtual fragment screening methodologies on 
hit finding. When hit-to-lead programs are initiated, novelty of the hits is also a crucial point. 
To assess this, substructure and similarity searches were conducted in the ChEMBL 
bioactivity database (https://www.ebi.ac.uk/chembldb/ accessed 21 January 2014). D3 hits 
were checked against all compounds with bioactivity data measured on the five dopamine 
receptors, while H4 hits against compounds with bioactivity data measured on the four 
histamine receptors. Exact substructure searches provided hits for 10 and 17, and similarity 
searches revealed additional similar known structures (see Table 2 and Table 3). Compounds 
2, 4, 8, 15 and 18 proved to be truly novel ones, and others might also suggest potential 
unexplored growing vectors. Comparing the hit rates it can be seen that both X-ray structure 
and homology model were capable of providing useful hits in virtual screening, and in this 
particular case the homology model performed even better than the crystal structure. The 
superiority of the ensemble docking approach is not witnessed in this study. While for the D3 
receptor the latter provided a substantially higher hit rate, the homology model performed best 
for the H4 receptor even though it was not preliminarily optimized in retrospective 
enrichment studies. Based on these results we conclude that both single structure and 
ensemble docking is useful for virtual fragment screening and seem to be complementary as 
the overlap between hit sets was low. Consequently a combined approach would maximize 
the outcome of hit finding efforts. 
 
3.4. Binding modes 
 
While no H-bond or pharmacophoric constraints were applied during docking the majority of 
the virtual hits in all four hit lists were basic amines forming ionic or H-bond interactions with 
the conserved Asp110
3.32
 in D3 and the homologous Asp94
3.32
 in H4 or the other acidic 
residue Glu182
5.46
 also known to play an important role in the recognition of histamine in H4. 
In the case of the D3 receptor it was found that docked poses of the in vitro active fragments 
provided very similar binding modes in multiple representative receptor conformations 
obtained by molecular dynamics simulation. Also the fragment binding modes from the X-ray 
structure docking were pretty much similar to the ensemble binding modes further 
strengthening the probability of their biological significance [35]. For example the 
thiazolemethanamine 1 produced nine very similar binding modes in ensemble docking with 
the basic amine interacting with Asp110
3.32
, the thiazole ring encased between Phe346
6.52
 and 
Val111
3.33
 and the chlorophenyl moiety facing His349
6.55
 and Val350
6.56
 with the chlorine 
substituent preferably pointing to the former, though in three poses pointing to the latter. The 
docked pose for the crystal structure is similar, though a bit shifted towards Asp110
3.32
 and 
the chlorophenyl moiety rotated by 90 degrees and the chlorine pointing to Val350
6.56
 (Fig. 
4A). The tricyclic D3 fragment 2 is quite rigid and produced eleven very similar binding 
modes and also the binding mode in the crystal structure was almost identical. The basic 
amine group again forms an ionic H-bond to Asp110
3.32
 and the aromatic ring almost overlaps 
with the chlorophenyl moiety of fragment 1. In a few structures an H-bond between the 
fragment amide N-H and the hydroxyl group of Ser196
5.46
 or the backbone carbonyl of 
Ser192
5.42
 is percepted (Fig. 4B). In the case of the H4 receptor the picture was not as clear as 
for D3. There was substantially higher variability among docked poses in the ensemble 
approach and binding modes from docking to the homology model produced different results 
in more cases. The major cause for this was probably the different rotamer state of Glu182
5.46
 
in the homology model and in most of the representative frames from MD. Compound 9 for 
example produced a variety of binding modes probably because of its multiple H-bond donor 
sites, though it got good docking scores both in the homology model and in the representative 
receptor conformations. Several similar poses were obtained for aminoquinoline 10, in which 
the primary amine forms an ionic H-bond to Asp94
3.32
, a cation-π interaction with Phe3447.39 
and the protonated quinoline nitrogen forms another ionic H-bond to Glu182
5.46
. In the 
homology model the fragment is shifted towards the extracellular side of the pocket because 
of the greater distance between the two acidic sites, the quinoline ring is flipped and the 
anilinic N-H forms an additional H-bond to the phenolic OH of Tyr319
6.51
 (Fig. 4C). Since 
this fragment was in the hit list from the homology model docking, the latter binding mode 
appears to be more feasible. For the tricyclic 18 seven similar poses were found in which the 
aliphatic amine group interacts with Asp94
3.32
 and the carboaliphatic ring is encased between 
Tyr95
3.33
, Met150
4.60
 and Leu175
5.39
. However, in four of these poses the protonated pyridine, 
while in three poses the anilinic N-H forms an H-bond with Glu182
5.46
. The pose found in the 
homology model differs from both of them: it is rotated by 90° with the aliphatic amine again 
interacting with Asp94
3.32
, the anilinic N-H with Glu182
5.46
 the protonated pyridine with 
Gln347
7.42
 and the carboaliphatic ring pointing towards the intracellular cavity of the binding 
site (Fig. 4D). Since this fragment was in the hit list from ensemble docking, the former 
binding mode appears to be more feasible. These findings underpin the superior hit rate for 
D3 and the inferior hit rate for H4 of the ensemble approach against the single structure hit 
rates. Also the higher binding affinities of D3 fragments correspond to the lower variability of 
their predicted binding modes [35]. 
 
4. Conclusions 
 
In silico methods of fragment-based lead discovery have not yet been widely investigated for 
GPCR targets. In the present study we have evaluated prospective structure based virtual 
screening methodologies on two GPCR targets namely the dopamine D3 and the histamine 
H4 receptors and a fragment library of 12905 compounds. For both targets single structure 
and ensemble docking screens were performed. For the D3 receptor the X-ray structure with 
eticlopride was available for the single structure screen, while a previously constructed H1 
receptor based homology model of H4 was utilized. Representative receptor conformations 
for ensemble docking were generated by molecular dynamics simulations. Around 50 virtual 
hits from both methodologies for both receptors were measured in vitro and with a greater 
than 20% inhibition at 10 μM criterion confirmed hit rates ranged from 16% to 32%. The 
reported hits provided high LE and low LELP values and are suitable starting points for hit-
to-lead optimization. Analysis of the obtained binding modes provided insight to the variation 
in hit rates of the different methodologies. It was found that the X-ray structure, the homology 
model and structural ensembles are all suitable for docking based virtual screening of 
fragments against these GPCRs. However, there was little overlap among their hit sets and 
were thus complementary to each other. Combined approaches should provide valuable 
starting points for fragment-based lead discovery for other GPCRs as well if an X-ray 
structure or a good quality homology model is available. 
 
5. Experimental 
 
5.1 Human recombinant D3 binding assay 
 
Cell cultures (CHO-K1) expressing human D3 receptors (purchased from HD Euroscreen 
Fast, Belgium) were homogenized in buffer solution (composition: 15 mM Tris, 2 mM 
MgCl2, 0,3 mM EDTA, 1 mM EGTA, pH=7.4 at 25°C) in  4x v/w with a Dounce tissue 
grinder and centrifuged at 40000 g at 4°C for 25 min. The supernatant was removed and the 
pellet was resuspended in 4x v/w buffer and recentrifuged. This process was repeated twice 
more and the pellet was resuspended in buffer (composition: 75 mM Tris, 12,5 mM MgCl2, 
0,3 mM EDTA, 1 mM EGTA, 250 mM Sucrose, pH=7.4 at 25°C) at a volume of 12,5 mL/g 
original weight. The preparations were then aliquoted and stored at -70°C.  
The aliquoted membrane was thawed and washed once in binding buffer containing 50 mM 
Tris-HCl; 5 mM MgCl2, 5 mM KCl; 1 mM CaCl2, 120 mM NaCl, 1 mM EDTA. In the same 
buffer 3,3 µg protein/assay was incubated with 2 nM [3H]raclopride in the presence or 
absence of test compound (to determine the binding inhibition of the test compound or the 
total binding, respectively) for 120 minutes at 25°C at a volume of 250 µL in 96 Deep Well 
plate. Non-specific binding was determined in the presence of 10 µM haloperidol. After 
incubation, samples were filtered over UniFilter
®
 GF/B
TM
 using PerkinElmer Harvester and 
washed with 4x1 mL ice-cold binding buffer. The plate was dried at 40°C for an hour and 40 
µL Microscint scintillation cocktail (PerkinElmer) was added to each well. The radioactivity 
was determined in MicroBeta 2450 microplate counter (PerkinElmer). 
SEM was lower than 15% for single concentration measurements and lower than 7% for the 
hits. The ligand displacement experiments were repeated at least two times. The specific 
radioligand binding is defined as the difference between total binding and the non-specific 
binding determined in the presence of an excess amount of haloperidol. IC50 values (i.e. 
concentration of compound giving 50% inhibition of specific binding) were determined from 
concentration-displacement curves by sigmoidal fitting. The inhibition constants (Ki) were 
calculated using the Cheng-Prusoff equation: Ki = IC50/[1+(L/KD)], where [L] is the free 
radioligand concentration and KD the affinity of the labeled ligand for receptor. KD was 
determined from the Scatchard plot. GraFit 6.0 (Erithracus Software, Horley, UK) software 
was used for curve fittings. 
 
5.2 Human recombinant H4 binding assay 
 
Membranes from CHO-K1 cells expressing human histamine H4 receptors were purchased 
from PerkinElmer Life and Analytical Sciences (Cat. No. ES-393-M400UA). Frozen 
membrane aliquots were thawed at room temperature and diluted to 200-fold (15 µg 
protein/500µL diluted membrane/well) with binding buffer (50 mM TRIS-HCl pH 7.4, 5 mM 
EDTA). 
The assay was performed according to the PerkinElmer assay protocol for human H4 
receptor: 500 µL diluted membrane suspension (15 µg protein/assay) was incubated with 
[
3
H]histamine as radioligand . Final reaction volume was 550 µL and final radioligand 
concentration was 4-7 nM. 10 µM histamine was used for determination of non-specific 
binding. The samples were incubated at 27C for 30 min and binding was terminated by 
vacuum filtration through Whatman GF/B glass fiber filters, pre-soaked in 0.5 % PEI. The 
filters were washed 3-times with 4 mL ice cold binding buffer. Filters were transferred to 
vials, 4 mL Optiphase HiSafe scintillation cocktail (PerkinElmer) was added and radioactivity 
was determined by Packard TriCarb 2900 TR (PerkinElmer) liquid scintillation counter. 
SEM was lower than 15% for single concentration measurements and lower than 7% for the 
hits. The ligand displacement by the compounds was determined using a minimum of six 
concentrations in duplicate or triplicate, and experiments were repeated at least two times. 
The specific radioligand binding is defined as the difference between total binding and the 
non-specific binding determined in the presence of an excess of unlabelled ligand. IC50 values 
(i.e. concentration of compound giving 50% inhibition of specific binding) were determined 
from concentration-displacement curves by sigmoidal fitting using Prism Software 4.0 
(GraphPad, San Diego, CA, U.S.A.). Ki values (i.e. inhibition constants) were calculated 
using the Cheng-Prusoff equation: Ki = IC50/[1+(L/KD)], where [L] is the free radioligand 
concentration and KD the affinity of the labelled ligand for receptor. KD was determined from 
the Scatchard plot. 
 
Supporting information 
 
Contains property distributions and diversity assessment of the fragment collection and dose-
response curves of the exemplified fragment hits. 
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Highlights 
 
- A library of 12905 fragments was virtually screened by docking against two GPCRs. 
- The D3 X-ray structure, a H4 homology model and representative frames for both receptors 
from MD were used. 
- Single structure and ensemble docking hit rates ranged from 16% to 32%. 
- Overlap between hit sets was low, methodologies were complementary. 
- Structural background of hit rates was analyzed.  
 
Abbreviations: GPCR: G protein-coupled receptor; FBLD: fragment-based lead discovery; 
LE: ligand efficiency; LELP: ligand-efficiency-dependent lipophilicity; MD: molecular 
dynamics; IFD: induced fit docking; POPC: 1-palmitoyl-2-oleoylphosphatidylcholine; 
RMSD: root-mean-square deviation; SP: single precision. 
 
Graphical abstract 
 
 
  
 
Fig. 1. Ligand structures and binding pockets of the initial receptor structures. A) Homology 
model of the human histamine H4 receptor in complex with JNJ7777120; B) X-ray structure 
of the human dopamine D3 receptor in complex with eticlopride. Receptors are represented as 
ribbons (helix 6 omitted for clarity) with interacting amino acids and ligands in grey and 
green skeletons, respectively and H-bonds in orange dash line. 
 
 
 
Fig. 2. Conformational variability of the binding sites: χ1 and χ2 side chain angles of binding 
site amino acids for each representative molecular dynamics frame in A) the H4 receptor and 
B) the D3 receptor. Angles are color coded according to the legend. 
  
 
Fig. 3. Log-linear plot of fragment rank averages and standard deviations of ranks in the 
ensemble docking approach for A) the D3 receptor and B) for the H4 receptor. Rank standard 
deviation is plotted against rank average calculated from the ranks obtained in the 
representative receptor structures for the 12905 fragments. Markers are size and color coded 
by the number of receptor frames in which the fragment fell within the top 1% of the ranked 
library. 
 
 
 
 
Fig. 4. Interaction modes of selected fragment hits obtained by single structure and ensemble 
docking. A) 1 in the D3 binding pocket; B) 2 in the D3 binding pocket; C) 10 in the H4 
binding pocket; D) 18 in the H4 binding pocket. Selected interacting amino acids of the 
crystal structure and the homology model are shown in light blue skeleton, those of the 
representative MD frames in grey, single structure docked fragment poses in orange and 
ensemble docked poses in green skeletons. In A) and B) Phe346
6.52
, Val350
6.56
 and Ser196
5.46
 
are omitted for clarity. In C) and D) Tyr319
6.51
 and Leu175
5.39
 are omitted for clarity. 
 
   D3 H4 
combined hit rate 25/92 (27%) 15/85 (18%) 
single structure hit rate 9/50 (18%) 11/50 (22%) 
ensemble docking hit rate 18/56 (32%) 8/50 (16%) 
overlap between hit sets 2/25 (8%) 4/15 (27%) 
 
Table 1. Hit rate statistics for the two receptors considered in this study. Hits are defined as 
showing higher than 20% inhibition in the D3 and H4 radioligand binding assays. 
 cpd Structure hD3 Ki / µM LE LELP XRD MD Closest known D1-5R ligand 
1 
 
0.17 0.66 3.7  + 
 
2 
 
0.50 0.57 1.2 + + 
 
3 
 
0.59 0.61 4.4  + 
 
4 
 
1.1 0.63 0.7  + 
 
5 
 
1.1 0.74 2.7 +  
 
6 
 
1.6 0.66 4.2  + 
 
7 
 
2.8 0.47 5.6 +  
 
8 
 
2.8 0.40 4.2  + 
 
 
Table 2. Experimental binding affinities of selected fragment hits of the D3 receptor and their LE and LELP values. The origin of the hit is 
indicated in the XRD and MD columns with + meaning the fragment was a virtual hit in the crystal structure docking or in the ensemble docking, 
respectively. Closest structural analogs from ChEMBL with measured binding affinity or functional activity against any of the five dopamine 
receptors are also indicated. 
 
cpd Structure hH4 Ki / µM LE LELP HM MD Closest known H1-4R ligand 
9 
 
8.4 0.35 6.4 + + 
 
10 
 
12.6 0.45 2.1 +  
 
11 
 
14.3 0.39 7.1 +  
 
12 
 
20.6 0.34 8.3 +  
 
13 
 
21.9 0.32 9.3 +  
 
14 
 
32.0 0.31 7.4 +  
 
15 
 
32.9 0.36 5.4 + + 
 
16 
 
58.4 0.32 8.0 + + 
 
17 
 
58.7 0.32 8.1 +  
 
18 
 
75.1 0.37 2.3  + 
 
 
Table 3. Experimental binding affinities of selected fragment hits of the H4 receptor and their LE and LELP values. The origin of the hit is 
indicated in the HM and MD columns with + meaning the fragment was a virtual hit in the homology model docking or in the ensemble docking, 
respectively. Closest structural analogs from ChEMBL with measured binding affinity or functional activity against any of the four histamine 
receptors are also indicated. 
 
